Write in a clean editor, then format for ESMO Gastrointestinal Oncology in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
ESMO Gastrointestinal Oncology is a peer-reviewed journal published by Elsevier, covering Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Esophageal Cancer Research and Treatment.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, ESMO Gastrointestinal Oncology 12 (2023) 45–58.
Formats any DOI in ESMO Gastrointestinal Oncology style. No sign-up. |
| Publishes research in | Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Esophageal Cancer Research and Treatment Pancreatic and Hepatic Oncology Research Cancer Immunotherapy and Biomarkers |
| ISSN | 2949-8198 |
| Citation impact (2-yr) | 1.21 |
| h-index | 8 |
| i10-index | 7 |
| Total citations | 381 |
| Open access | Yes |
| Top institutions publishing here | National Cancer Center Hospital East |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Immune checkpoint inhibition (ICI) has revolutionized cancer therapy, including treatment of hepatocellular carcinoma (HCC) which comprises 80%-90% of all liver cancers, the third most common cause of cancer-related death worldwide. The main targeted pathways are the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoints. Blockade of CTLA-4…
•HER2 amplification is detected in ∼5% of metastatic CRC with wild-type KRAS.•The targeting of HER2 amplification is an established approach in metastatic CRC, with promising results.•The emergence of highly potent agents has led to a new concept of HER2-low disease in various malignancies, including CRC.•The prevalence of HER2-low disease in mCRC is between 6% and…
Background: Evaluating multiple biomarkers including human epidermal growth factor receptor 2 (HER2), mismatch repair (MMR) status, programed death-ligand 1 (PD-L1), and claudin 18.2 (CLDN18.2) is essential for selecting appropriate first-line therapy of metastatic gastroesophageal adenocarcinoma (mGEA). However, this can be challenging if tumor tissue amount is limited and may cause delays in the initiation of…
Background: The global phase III SPOTLIGHT and GLOW trials confirmed the superiority of zolbetuximab plus chemotherapy over chemotherapy alone for claudin 18.2-positive advanced gastric cancer (AGC). However, severe nausea/vomiting during zolbetuximab infusion remains a significant safety concern. Our study aimed to evaluate the safety management strategy's applicability in our institution. Patients and methods: -receptor antagonist…
Background: This study aims to develop consensus-based guidelines to prevent and manage nausea and vomiting in patients treated with zolbetuximab plus chemotherapy. Materials and methods: An international Delphi panel included 15 experts who were involved in phase II or III clinical studies of zolbetuximab. A rating survey was developed, informed by literature and clinical experience,…
